Cargando…

Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial

BACKGROUND: The prevalence of type 2 diabetes is increasing in epidemic proportions in low- and middle-income countries. There is an urgent need for novel methods to tackle the increasing incidence of diabetes. The ubiquity of mobile phone use and access to Internet makes mobile health (mHealth) tec...

Descripción completa

Detalles Bibliográficos
Autores principales: Muralidharan, Shruti, Mohan, Viswanathan, Anjana, Ranjit Mohan, Jena, Sidhant, Tandon, Nikhil, Allender, Steven, Ranjani, Harish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743924/
https://www.ncbi.nlm.nih.gov/pubmed/29233806
http://dx.doi.org/10.2196/resprot.8644
_version_ 1783288651135844352
author Muralidharan, Shruti
Mohan, Viswanathan
Anjana, Ranjit Mohan
Jena, Sidhant
Tandon, Nikhil
Allender, Steven
Ranjani, Harish
author_facet Muralidharan, Shruti
Mohan, Viswanathan
Anjana, Ranjit Mohan
Jena, Sidhant
Tandon, Nikhil
Allender, Steven
Ranjani, Harish
author_sort Muralidharan, Shruti
collection PubMed
description BACKGROUND: The prevalence of type 2 diabetes is increasing in epidemic proportions in low- and middle-income countries. There is an urgent need for novel methods to tackle the increasing incidence of diabetes. The ubiquity of mobile phone use and access to Internet makes mobile health (mHealth) technology a viable tool to prevent and manage diabetes. OBJECTIVE: The objective of this randomized controlled trial is to implement and evaluate the feasibility, cost-effectiveness, and sustainability of a reality television–based lifestyle intervention program. This intervention program is delivered via a mobile phone app (mDiab) to approximately 1500 Android smartphone users who are adults at a high risk for type 2 diabetes from three cities in India, namely, Chennai, Bengaluru, and New Delhi. METHODS: The mDiab intervention would be delivered via a mobile phone app along with weekly coach calls for 12 weeks. Each participant will go through a maintenance phase of 6 to 8 months post intervention. Overall, there would be 3 testing time points in the study: baseline, post intervention, and the end of follow-up. The app will enable individuals to track their weight, physical activity, and diet alongside weekly video lessons on type 2 diabetes prevention. RESULTS: The study outcomes are weight loss (primary measure of effectiveness); improvement in cardiometabolic risk factors (ie, waist circumference, blood pressure, glucose, insulin, and lipids); and improvement in physical activity, quality of life, and dietary habits. Sustainability will be assessed through focus group discussions. CONCLUSIONS: If successful, mDiab can be used as a model for translational and implementation research in the use of mHealth technology for diabetes prevention and may be further expanded for the prevention of other noncommunicable diseases such as hypertension and cardiovascular diseases. TRIAL REGISTRATION: Clinical Trials Registry of India CTRI/2015/07/006011 http://ctri.nic.in/Clinicaltrials/pdf_generate.php? trialid=11841 (Archived by WebCite at http://www.webcitation.org/6urCS5kMB)
format Online
Article
Text
id pubmed-5743924
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-57439242018-01-04 Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial Muralidharan, Shruti Mohan, Viswanathan Anjana, Ranjit Mohan Jena, Sidhant Tandon, Nikhil Allender, Steven Ranjani, Harish JMIR Res Protoc Protocol BACKGROUND: The prevalence of type 2 diabetes is increasing in epidemic proportions in low- and middle-income countries. There is an urgent need for novel methods to tackle the increasing incidence of diabetes. The ubiquity of mobile phone use and access to Internet makes mobile health (mHealth) technology a viable tool to prevent and manage diabetes. OBJECTIVE: The objective of this randomized controlled trial is to implement and evaluate the feasibility, cost-effectiveness, and sustainability of a reality television–based lifestyle intervention program. This intervention program is delivered via a mobile phone app (mDiab) to approximately 1500 Android smartphone users who are adults at a high risk for type 2 diabetes from three cities in India, namely, Chennai, Bengaluru, and New Delhi. METHODS: The mDiab intervention would be delivered via a mobile phone app along with weekly coach calls for 12 weeks. Each participant will go through a maintenance phase of 6 to 8 months post intervention. Overall, there would be 3 testing time points in the study: baseline, post intervention, and the end of follow-up. The app will enable individuals to track their weight, physical activity, and diet alongside weekly video lessons on type 2 diabetes prevention. RESULTS: The study outcomes are weight loss (primary measure of effectiveness); improvement in cardiometabolic risk factors (ie, waist circumference, blood pressure, glucose, insulin, and lipids); and improvement in physical activity, quality of life, and dietary habits. Sustainability will be assessed through focus group discussions. CONCLUSIONS: If successful, mDiab can be used as a model for translational and implementation research in the use of mHealth technology for diabetes prevention and may be further expanded for the prevention of other noncommunicable diseases such as hypertension and cardiovascular diseases. TRIAL REGISTRATION: Clinical Trials Registry of India CTRI/2015/07/006011 http://ctri.nic.in/Clinicaltrials/pdf_generate.php? trialid=11841 (Archived by WebCite at http://www.webcitation.org/6urCS5kMB) JMIR Publications 2017-12-12 /pmc/articles/PMC5743924/ /pubmed/29233806 http://dx.doi.org/10.2196/resprot.8644 Text en ©Shruti Muralidharan, Viswanathan Mohan, Ranjit Mohan Anjana, Sidhant Jena, Nikhil Tandon, Steven Allender, Harish Ranjani. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 12.12.2017. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
Muralidharan, Shruti
Mohan, Viswanathan
Anjana, Ranjit Mohan
Jena, Sidhant
Tandon, Nikhil
Allender, Steven
Ranjani, Harish
Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial
title Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial
title_full Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial
title_fullStr Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial
title_full_unstemmed Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial
title_short Mobile Health Technology (mDiab) for the Prevention of Type 2 Diabetes: Protocol for a Randomized Controlled Trial
title_sort mobile health technology (mdiab) for the prevention of type 2 diabetes: protocol for a randomized controlled trial
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743924/
https://www.ncbi.nlm.nih.gov/pubmed/29233806
http://dx.doi.org/10.2196/resprot.8644
work_keys_str_mv AT muralidharanshruti mobilehealthtechnologymdiabforthepreventionoftype2diabetesprotocolforarandomizedcontrolledtrial
AT mohanviswanathan mobilehealthtechnologymdiabforthepreventionoftype2diabetesprotocolforarandomizedcontrolledtrial
AT anjanaranjitmohan mobilehealthtechnologymdiabforthepreventionoftype2diabetesprotocolforarandomizedcontrolledtrial
AT jenasidhant mobilehealthtechnologymdiabforthepreventionoftype2diabetesprotocolforarandomizedcontrolledtrial
AT tandonnikhil mobilehealthtechnologymdiabforthepreventionoftype2diabetesprotocolforarandomizedcontrolledtrial
AT allendersteven mobilehealthtechnologymdiabforthepreventionoftype2diabetesprotocolforarandomizedcontrolledtrial
AT ranjaniharish mobilehealthtechnologymdiabforthepreventionoftype2diabetesprotocolforarandomizedcontrolledtrial